Human hepatocyte genome

The human hepatocyte genome comprises the complete set of genetic information within a liver cell, including both nuclear and mitochondrial DNA (NIH, 2023). It serves as the fundamental blueprint for the liver's diverse functions, such as nutrient metabolism, bile production, and the synthesis of plasma proteins. While the genome itself is a broad biological entity rather than a specific protein target, it is the primary site of action for emerging genomic medicines like CRISPR-Cas9 and base editing (Nature Reviews Genetics, 2022). These therapies are designed to target specific loci within the hepatocyte genome to treat hereditary diseases like transthyretin amyloidosis and hemophilia by correcting or silencing defective genes. Drugs like NTLA-2001 utilize lipid nanoparticles to deliver gene-editing components directly to hepatocytes, where they modify the genomic sequence to achieve a permanent therapeutic effect (Intellia Therapeutics, 2021). However, targeting the genome presents unique challenges, including the risk of off-target mutations and the need for highly efficient delivery to the liver. Monitoring the safety and efficacy of such interventions often involves measuring circulating biomarkers or assessing genomic stability through advanced sequencing techniques. Overall, the hepatocyte genome represents a critical frontier in precision medicine for metabolic and genetic disorders.

Other names

Hepatocyte DNALiver cell genomeHuman liver genomeHepatocyte genomic DNA

Therapeutic strategies include site-specific gene editing via CRISPR-Cas9, base editing, and gene replacement using viral vectors, as well as DNA damage induced by topoisomerase inhibitors (Nature, 2021; PubChem).